

### 3rd Lung MCMC (Multidisciplinary Cancer Management Course)

A joint initiative of ASCO, ISSLC, PGIMER and TMC in collaboration with Lung Cancer Education Society

#### DAY ONE - MARCH 24, 2018 (SATURDAY)

08.00 – 08.50	<b>REGISTRATION</b>	
08.50 – 09.25	<b>Introductory Session</b>	
08.50 – 08.55	Welcome Remarks	Navneet Singh
08.55 – 09.10	ASCO Presentations	Vanessa Sarchet
09.10 – 09.22	Epidemiology of Lung Cancer (Global & Indian)	TBA
09.22 – 09.25	Discussion (Q & A)	
09.25 – 10.40	<b>Session 1 (Diagnosis of Lung Cancer)</b>	
09.25 – 09.37	Clinical features that lead to suspicion of lung cancer	KT Prasad
09.37 – 09.40	Discussion (Q & A)	
	<b>Essentials of Imaging in Lung Cancer</b>	
09.40 – 09.50	Radiological Imaging in Lung Cancer (CT Thorax; MRI Brain)	Nilendu Purandare
09.50 – 10.00	Nuclear Imaging in Lung Cancer (Bone Scan & PET/PET-CT)	Anish Bhattacharya
10.00 – 10.05	Discussion (Q & A)	
	<b>Essentials of Pathological Testing in Lung Cancer</b>	
10.05 – 10.15	Biopsy specimens	Amanjit Bal
10.15 – 10.25	FNAC, fluid specimens & cell blocks	Nalini Gupta
10.25 – 10.35	Molecular testing	Anuradha Choughule
10.35 – 10.40	Discussion (Q & A)	
10.40 – 10.55	<b>Welcome of delegates by Director &amp; Dean (Research), PGIMER</b>	
10.55 – 11.15	<b>TEA BREAK</b>	
11.15 – 12.00	<b>Session 2 (Staging of Lung Cancer)</b>	
11.15 – 11.27	Current TNM staging for lung cancer	Ramon Rami-Porta
11.27 – 11.30	Discussion (Q & A)	
	<b>Mediastinal Staging Procedures in Lung Cancer</b>	
11.30 – 11.43	Endoscopic staging (EBUS, EUS, EBUS + EUS)	Sahajal Dhooria
11.43 – 11.56	Invasive (surgical) staging (including mediastinoscopy)	Sabita Jiwnani
11.56 – 12.00	Discussion (Q & A)	

### 3rd Lung MCMC (Multidisciplinary Cancer Management Course)

A joint initiative of ASCO, ISSLC, PGIMER and TMC in collaboration with Lung Cancer Education Society

#### DAY ONE - MARCH 24, 2018 (SATURDAY)

<b>12.00 – 12.40</b>	<b>Session 3 (Panel Discussion On Diagnosis And Staging)</b>	
	Moderator: Anant Mohan	
<b>12.45 – 13.30</b>	<b>Industry Sponsored Satellite Symposium 1</b>	<b>Boehringer Ingelheim</b>
<b>13.30 – 14.15</b>	<b>LUNCH BREAK</b>	
<b>14.15 – 15.00</b>	<b>Session 4 (Early Stage NSCLC)</b>	
14.15 – 14.27	Pre-operative evaluation and assessment for fitness for surgery	TBA
14.27 – 14.30	Discussion (Q & A)	
14.30 – 14.42	Principles of surgical management of early stage NSCLC (including importance of Complete Resection)	CS Pramesh
14.42 – 14.45	Discussion (Q & A)	
14.45 – 14.57	Management of medically inoperable early stage NSCLC (SBRT)	Suresh Senan
14.57 – 15.00	Discussion (Q & A)	
<b>15.00 – 15.40</b>	<b>Session 5 (Multidisciplinary Tumor Board - Early Stage NSCLC)</b>	
	Moderator: Sabita Jiwnani	
<b>15.40 – 16.00</b>	<b>TEA BREAK</b>	
<b>16.00 – 16.30</b>	<b>Session 6 (Locally Advanced NSCLC)</b>	
16.00 – 16.12	Differentiating IIIA vs IIIB vs IIIC: Radiation Oncologist's perspective	Suresh Senan
16.12 – 16.15	Discussion (Q & A)	
16.15 – 16.27	Differentiating IIIA vs IIIB vs IIIC: Surgical Oncologist's perspective	Ramon Rami Porta
16.27 – 16.30	Discussion (Q & A)	
<b>16.30 – 17.10</b>	<b>Session 7 (Multidisciplinary Tumor Board – Locally Advanced NSCLC)</b>	
	Moderator: CS Pramesh	
<b>17.15 – 18.00</b>	<b>Industry Sponsored Satellite Symposium 2</b>	<b>Pfizer</b>
<b>18.00 – 18.45</b>	<b>Industry Sponsored Satellite Symposium 3</b>	<b>BMS</b>
<b>19:30</b>	<b>DINNER</b>	

### 3rd Lung MCMC (Multidisciplinary Cancer Management Course)

A joint initiative of ASCO, ISSLC, PGIMER and TMC in collaboration with Lung Cancer Education Society

#### DAY TWO - MARCH 25, 2018 (SUNDAY)

<b>08.30 – 09.15</b>	<b>Session 8 (Metastatic NSCLC with driver mutations/rearrangements)</b>	
08.30 – 08.45	Biomarker Testing in Metastatic NSCLC (EGFR-ALK-ROS1; Others)	Ming Tsao
08.45 – 08.50	Discussion (Q & A)	
08.50 – 09.10	Precision Medicine for metastatic NSCLC with driver mutations/rearrangements (EGFR-ALK-ROS1; Others)	Tony Mok
09.10 – 09.15	Discussion (Q & A)	
<b>09.15 – 09.55</b>	<b>Session 9 (Multidisciplinary Tumor Board – Metastatic NSCLC with driver mutations/rearrangements)</b>	
	Moderator: Kumar Prabhash	
<b>10.00 – 10.30</b>	<b>Industry Sponsored Satellite Symposium 4</b>	<b>Novartis</b>
<b>10.30 – 10.50</b>	<b>TEA BREAK</b>	
<b>10.50 – 11.40</b>	<b>Session 10 (Metastatic NSCLC without driver mutations/rearrangements)</b>	
10.50 – 11.02	PD-L1 testing in lung cancer (Blueprint Project)	Ming Tsao
11.02 – 11.05	Discussion (Q & A)	
	<b>Immune Check Point Inhibitor Therapy for stage IV NSCLC</b>	
11.05 – 11.20	Principles of Immune Check Point Inhibitor Therapy	Tony Mok
11.20 – 11.35	Identifying & Managing Toxicities with Immune Check Point Inhibitors	Kumar Prabhash
11.35 – 11.40	Discussion (Q & A)	
<b>11.40 – 12.25</b>	<b>Session 11 (Multidisciplinary Tumor Board – Metastatic NSCLC without driver mutations/rearrangements)</b>	
	Moderator: Ullas Batra	
<b>12.30 – 13.15</b>	<b>Industry Sponsored Satellite Symposium 5</b>	<b>Astra Zeneca</b>
<b>13.15 – 14.00</b>	<b>LUNCH BREAK</b>	

### 3rd Lung MCMC (Multidisciplinary Cancer Management Course)

A joint initiative of ASCO, ISSLC, PGIMER and TMC in collaboration with Lung Cancer Education Society

<b>14.00 – 14.45</b>	<b>Session 12 (SCLC)</b>	
14.00 – 14.12	Treating SCLC using TNM staging: Does it make a difference?	JP Agarwal
14.12 – 14.15	Discussion (Q & A)	
<b>14.15 – 14.45</b>	<b>Multidisciplinary Tumor Board</b>	
	Moderator: Amit Joshi	
<b>14.50 – 15.10</b>	<b>Industry Sponsored Satellite Symposium 6</b>	<b>DRL</b>
<b>15.10 – 15.30</b>	<b>TEA BREAK</b>	
<b>15.30 – 16.00</b>	<b>Session 13 (Supportive and Palliative Care)</b>	
15.30 – 15.42	Prognostic markers for lung cancer	Prabhat Malik
15.42 – 15.45	Discussion (Q & A)	
15.45 – 15.57	Early integration of palliative care with standard oncological care	Sushmita Ghoshal
15.57 – 16.00	Discussion (Q & A)	
<b>16.00 – 16.45</b>	<b>Session 14 (Lung Cancer in Resource Constrained Setting)</b>	
	Panel discussion on challenges related to lung cancer in resource constrained settings: 1) Diagnosis and treatment issues in tuberculosis endemic regions 2) Availability & cost of platforms for predictive biomarker testing 3) Availability and cost of novel targeted therapies and immune check point inhibitors 4) Awareness and adherence to multidisciplinary management	
	Moderator: Navneet Singh	
16.45 – 17.00	<b>Concluding Remarks &amp; Wrap-up</b>	<b>Navneet Singh, CS Pramesh &amp; Vanessa Sarchet</b>